Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fufang Tongluo Decoction as an Adjunct to Aspirin and Atorvastatin in Ischemic Moyamoya Disease
NCT07875335Enrolling by invitation
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Dec 2024
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Randomised, double-blind trial in Moyamoya disease comparing Aspirin + Atorvastatin + Fufang Tongluo Decoction with Aspirin + Atorvastatin + Fufang Tongluo Placebo (2 arms). Primary endpoint: Percentage of Participants With an Increase of at Least 1 Point in Cerebral Perfusion Staging Score at 3 months. Started Dec 2024; status: enrolling by invitation.
02
Drugs
Fufang Tongluo Decoction
03
Conditions
Moyamoya disease
Beyond the preview
Go deeper on NCT07875335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07875335.